ArticleNeurochemical research2025
PAK1 Is Involved in Epileptogenesis by Regulating the Synaptic Plasticity of Hippocampal Neurons Through LIMK.
Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PAK1, a key regulator of cytoskeletal remodeling, is associated with synaptic plasticity, but its role in epilepsy remains unclear. This study investigated whether PAK1 contributes to epileptogenesis by modulating hippocampal synaptic plasticity via the LIMK signalling pathway. A chronic epilepsy model was induced in mice via the use of pentylenetetrazol (PTZ). LV-PAK1-shRNA was stereotactically injected into the hippocampus to downregulate PAK1. Seizure susceptibility was evaluated through seizure scores and latency to kindling. Western blotting was used to assess the expression of PAK1, LIMK1/2, and phosphorylated LIMK1/2 (p-LIMK1/2). Golgi-Cox staining and transmission electron microscopy were used to analyze dendritic spine density and the number of synaptic vesicles in the CA1 region. Epileptic mice presented increased hippocampal expression of PAK1, LIMK1/2, and p-LIMK1/2. PAK1 knockdown reduced LIMK1/2 and p-LIMK1/2 levels, decreased seizure severity, and delayed epileptogenesis. It also significantly reduced the dendritic spine density and number of synaptic vesicles in CA1 neurons. PAK1 may contribute to epileptogenesis by regulating dendritic spine formation and synaptic vesicle availability via the LIMK pathway, highlighting its potential as a therapeutic target for epilepsy.
Indexed as
Identifiers
41307641What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.